Retatrutide Protocol: Complete Cycling & Dosing Guide

Overview

Retatrutide (LY3437943) is a triple receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. This combination creates a synergistic metabolic effect superior to dual agonists, producing weight loss outcomes of 20-24% body weight at therapeutic doses. Currently in investigational status, retatrutide is obtained through research channels and represents one of the most potent metabolic modulators available.

The compound works through three distinct mechanisms: GLP-1 receptor stimulation enhances insulin secretion and reduces appetite via central hypothalamic pathways; GIP receptor activation potentiates insulin release and amplifies anorectic effects; glucagon receptor agonism increases energy expenditure and hepatic fat oxidation. This triagonist approach addresses energy balance, carbohydrate metabolism, and fat utilization simultaneously.

Critical Understanding: Retatrutide is not approved by the FDA for human use outside clinical trials. This protocol is educational information only. All use carries significant regulatory and safety risks, including unknown purity from research vendors, potential for pancreatitis, gallbladder disease, and incomplete long-term safety data.

Standard Protocol

Baseline Requirements Before Starting

• Comprehensive metabolic panel (liver, kidney, pancreatic function)
• Fasting glucose and HbA1c
• Lipid panel
• Thyroid function (TSH, free T4)
• Caloric deficit established (minimum 300-500 calories daily)
• Adequate protein intake (1.0-1.2g per pound of body weight for metabolic support)
• Medical consultation documenting investigational compound use

Standard 12-Week Dosing Schedule

Retatrutide is administered as a once-weekly subcutaneous injection. Dose escalation occurs gradually to minimize gastrointestinal side effects.

Weeks 1-4: 2mg once weekly

• Starting dose allows receptor adaptation
• Most individuals tolerate 2mg with minimal nausea
• Mild appetite suppression begins around day 3-4

Weeks 5-8: 4mg once weekly

• Dose doubles; effects become more pronounced
• Nausea typically peaks during this phase, subsiding by week 7-8
• Weight loss acceleration begins (0.5-1.5 lbs weekly average)

Weeks 9-12: 6mg once weekly (or escalate to 8mg if well-tolerated)

• Full metabolic effects manifest
• Appetite suppression becomes significant
• Weekly weight loss 1.5-2.5 lbs at this dose
• Gastrointestinal tolerance should be established

Complete 20-Week Advanced Protocol

Users seeking maximal results extend the cycle:

Weeks 1-4: 2mg weekly Weeks 5-8: 4mg weekly Weeks 9-12: 6mg weekly Weeks 13-16: 8mg weekly (optional, based on tolerance and goals) Weeks 17-20: 10mg weekly (highest commonly used dose for fat loss)

Expected cumulative weight loss: 15-22% body weight depending on adherence, caloric deficit, and starting body composition.

Post-Cycle Management (Weeks 21-26)

After completing active dosing, allow a 6-week washout period:

• Taper is not necessary; discontinue after final injection
• Week 1 post-final injection: appetite returns progressively; maintain caloric structure
• Weeks 2-4: energy levels normalize; GI symptoms resolve completely
• Weeks 5-6: body composition stabilizes at new baseline

This washout prevents rebound appetite dysregulation and allows endogenous appetite signaling to recalibrate.

Goal-Specific Protocols

Protocol A: Maximum Fat Loss (Aggressive)

Duration: 20 weeks dosing + 6 weeks washout

Dosing: Escalate to 10-12mg weekly by week 18 Caloric Deficit: 500-700 calories daily Protein: 1.2g per pound lean body weight Training: Resistance training 4x weekly + 30-45 min steady-state cardio 3x weekly Expected Outcome: 20-24% body weight reduction; preserve 70-80% of lean mass

Weekly Weight Loss Timeline:

• Weeks 1-4: 0-0.5 lbs (adaptation phase)
• Weeks 5-8: 1-1.5 lbs weekly
• Weeks 9-16: 1.5-2.5 lbs weekly
• Weeks 17-20: 2-3 lbs weekly (maximal effect)

Protocol B: Metabolic Health & Body Recomposition

Duration: 12 weeks dosing + 6 weeks washout

Dosing: 6-8mg weekly maintenance after titration Caloric Deficit: 300-400 calories daily (moderate) Protein: 1.0-1.1g per pound lean body weight Training: Resistance 5x weekly (prioritize strength maintenance) + 20-30 min cardio 2x weekly Expected Outcome: 12-16% body weight reduction; maintain 85-90% of lean mass; improved insulin sensitivity and liver health

This approach prioritizes muscle retention while still achieving significant fat loss through metabolic improvements in insulin sensitivity and hepatic fat oxidation.

Protocol C: Liver Health Optimization

Duration: 16 weeks dosing + 6 weeks washout

Dosing: 8-12mg weekly (higher doses show 82.4% liver fat reduction) Caloric Deficit: 400-500 calories daily Supplement Stack: Milk thistle 300mg BID, NAC 1500mg daily Monitoring: Liver function tests at week 0, 8, and 16 Expected Outcome: 40-82% reduction in hepatic fat content; normalization of liver fat (<5%) in 80%+ of participants

Retatrutide demonstrates exceptional efficacy for metabolic dysfunction-associated steatotic liver disease (MASLD), with dose-dependent improvements up to 82.4% at the highest dose.

Protocol D: Minimal Intervention (Maintenance Focus)

Duration: 8 weeks dosing + 6 weeks washout

Dosing: 4-6mg weekly (no escalation beyond 6mg) Caloric Deficit: 200-300 calories daily Training: Maintenance resistance 3x weekly Expected Outcome: 6-10% body weight reduction; minimal GI side effects; improved glucose control

Suitable for individuals with lower obesity severity or those prioritizing side effect minimization.

How to Administer Step-by-Step

Reconstitution (Powder Form)

1. Prepare workspace: Clean table with alcohol wipes; gather sterile 1mL syringe, 29-30 gauge needle, bacteriostatic water for injection
2. Remove flip-cap: Do not touch rubber septum
3. Swab vial: Apply alcohol wipe to rubber septum; wait 30 seconds for drying
4. Draw bacteriostatic water: Using sterile syringe, draw prescribed volume (typically 1mL per vial to create 2mg/0.2mL concentration)
5. Inject water: Insert needle at 45-degree angle; inject water slowly into vial
6. Gently agitate: Do not shake vigorously; roll vial between palms for 1-2 minutes until powder fully dissolves
7. Allow settling: Wait 5 minutes; solution should be clear with no particles
8. Refrigerate: Store reconstituted vial at 2-8°C; stable for 28 days

Weekly Injection Protocol

1. Prepare injection site: Choose subcutaneous area (abdomen preferred; rotate: abdomen, thigh, upper arm weekly)
2. Swab site: Apply alcohol wipe; allow 30 seconds drying
3. Draw dose: Using new sterile syringe and needle (29-30 gauge), withdraw prescribed volume from vial
4. Pinch skin: Create small fold of skin/subcutaneous tissue
5. Insert needle: At 45-90 degree angle, insert needle fully into pinched skin
6. Inject: Depress plunger slowly over 5-10 seconds
7. Withdraw: Remove needle; apply light pressure with sterile gauze for 10 seconds
8. Dispose: Place needle/syringe in sharps container; never reuse

Storage Guidelines

• Unreconstituted powder: Room temperature (15-25°C) in original vial; stable 24 months
• Reconstituted solution: 2-8°C in refrigerator; stable 28 days maximum
• Transport: Use insulated travel case with ice pack if traveling; never freeze
• Post-injection: Store remaining reconstituted vial in back of refrigerator (consistent temperature)

Cycle Example: Week-by-Week Schedule

16-Week Fat Loss Protocol

Week 1: Monday 2mg subcutaneous injection, abdomen. Expect mild appetite suppression by Thursday.

Week 2: Monday 2mg injection, rotating to right thigh. Monitor for nausea (typical onset day 2-3, resolves by day 6).

Week 3-4: Monday 2mg injection, continue rotation. Adaptation phase complete; appetite suppression becomes consistent.

Week 5: Monday 4mg injection (first escalation), abdomen. Nausea typically returns for 3-4 days; manageable with small meals and ginger tea.

Week 6-8: Monday 4mg injection; rotate sites weekly. Weight loss acceleration begins week 6 (1-1.5 lbs weekly).

Week 9: Monday 6mg injection (second escalation), establishing new baseline dose. GI symptoms usually subside within 5 days.

Week 10-12: Monday 6mg injection; consistent weekly loss 1.5-2 lbs. Appetite suppression becomes pronounced; hunger signals minimal.

Week 13: Monday 8mg injection (third escalation), for advanced users. Significant nausea possible; manage with protein-focused liquid meals.

Week 14-16: Monday 8mg injection; final maintenance phase. Cumulative weight loss 15-20% by week 16. Final injection week 16 Monday.

Weeks 17-22: Washout phase; no injections. Appetite gradually returns over 2 weeks. Monitor weight stabilization.

What to Expect: Timeline of Effects

Days 1-3 (Post-Injection Window)

• Initial systemic exposure minimal
• Mild decrease in appetite possible by day 2
• No significant GI effects

Days 4-7 (Peak Effect Window)

• Maximum appetite suppression (40-70% reduction in hunger signals)
• Nausea most likely to occur during titration phases (typically days 3-5)
• Increased satiety; reduced food enjoyment/palatability
• Stable energy levels or mild fatigue possible

Weeks 2-4 (Steady-State Phase)

• Side effects minimize as body adapts
• Consistent appetite suppression (maintained until week 7-8 with dose escalation)
• Weekly weight loss 0.5-1.5 lbs depending on caloric adherence
• Improved fasting glucose and post-meal blood sugar stability

Weeks 5-8 (Dose Escalation Phase)

• Repeat nausea/GI symptoms for 3-5 days post-injection
• Tolerance rebuilds within 5-7 days
• Accelerating weight loss (1-1.5 lbs weekly)
• Reduced food cravings, especially for processed/sugar-containing foods

Weeks 9-12 (Full Dosing Phase)

• Peak metabolic effects; maximum weight loss (1.5-2.5 lbs weekly)
• Appetite suppression becomes subtle; simply no hunger (different from early nausea)
• Energy levels normalize
• Blood sugar control optimal

Weeks 13+ (Advanced Dosing Phase)

• If escalating to 8-12mg: repeat adaptation cycle for 5-7 days
• Maximal fat oxidation and hepatic improvements
• Cumulative weight loss becomes pronounced (3-5 lbs weekly possible)

Post-Cycle Weeks 1-6 (Washout Phase)

• Week 1: Appetite begins returning (day 2-3); hunger gradually increases
• Weeks 2-3: Appetite normalization; food enjoyment returns
• Weeks 4-6: Full appetite sensation restored; body composition stabilizes at new baseline
• Critical period: Maintain caloric structure; weight rebound occurs quickly if eating returns to pre-cycle patterns

Signs It's Working & When to Adjust

Positive Indicators (Week 2-3)

• Reduced hunger sensation (not necessarily nausea—true appetite suppression)
• Increased satiety per meal; smaller portions satisfy
• Weekly weight loss 0.5-1.5 lbs consistently
• Improved fasting glucose readings
• Improved energy during fasted cardio

When to Escalate Dose (Proceed to Next Protocol Level)

• Week 4 completion without significant nausea: advance to 4mg safely
• Weeks 5-8 completion with manageable GI effects: advance to 6mg
• Hunger returning despite dose: indicate receptor downregulation; escalate or increase caloric deficit slightly
• Weight loss plateau for 2+ consecutive weeks: escalate dose or tighten caloric deficit by 100 calories

When to Hold Current Dose

• Persistent nausea/vomiting lasting >7 days post-injection: delay next escalation one week
• Severe diarrhea interfering with daily function: reduce fiber temporarily; escalate when resolved
• Unexplained fatigue: assess sleep quality and caloric deficit; deficit may be too aggressive

When to Reduce or Discontinue

• Severe pancreatitis symptoms (upper abdominal pain, vomiting): stop immediately; seek medical attention
• Gallbladder symptoms (right upper quadrant pain, nausea with fatty meals): halt protocol; imaging indicated
• Uncontrollable vomiting lasting >3 days: reduce subsequent dose by 2mg or halt protocol
• Allergic reactions (rash, difficulty breathing): stop; do not re-initiate

Common Protocol Mistakes

Mistake 1: Inadequate Caloric Deficit

Issue: Expecting weight loss without dietary adherence. Retatrutide suppresses appetite but doesn't eliminate need for caloric deficit.

Solution: Track intake for minimum 2 weeks baseline; establish 300-500 calorie deficit, then begin protocol. Without deficit, weight loss stalls 8-10 weeks.

Mistake 2: Escalating Too Rapidly

Issue: Increasing dose before 4-week minimum at each level; causes prolonged nausea and potential compliance dropout.

Solution: Minimum 4 weeks per dose level before escalation. Tolerance window is individual; 6-week adaptation is acceptable.

Mistake 3: Insufficient Protein Intake During Weight Loss

Issue: Aggressive weight loss (24% body weight) causes 10-15% lean mass loss if protein insufficient. Retatrutide accelerates lean loss if dietary support absent.

Solution: Prioritize 1.0-1.2g per pound lean body weight daily. This reduces lean loss from 10-15% to 5-8% of total weight loss.

Mistake 4: Poor Site Rotation

Issue: Injecting same area repeatedly causes lipodystrophy, reduced absorption, inconsistent dosing.

Solution: Rotate between abdomen, left thigh, right thigh, left arm, right arm weekly. Vary injection site within each area (upper, middle, lower abdomen).

Mistake 5: Reconstitution Errors

Issue: Using non-sterile water, shaking vial vigorously (denatures peptide), or storing unreconstituted powder improperly.

Solution: Use only bacteriostatic water for injection. Gently roll—never shake—vial. Store powder at room temperature; reconstituted solution at 2-8°C maximum 28 days.

Mistake 6: Stopping Protocol After Side Effects

Issue: Discontinuing after first dose nausea; GI adaptation requires 5-7 days but is temporary.

Solution: Expect nausea days 2-5 on each escalation. Use ginger tea, smaller frequent meals, and plain broths. Symptoms subside reliably; they don't indicate failure.

Mistake 7: Continuing Identical Caloric Deficit Post-Cycle

Issue: Maintaining aggressive deficit during washout phase causes accelerated rebound weight gain.

Solution: During washout weeks 1-3, increase calories by 100-200 daily as appetite returns. By week 4, return to maintenance intake to stabilize new weight.

How to Stack with Other Compounds

Stacking with GLP-1 Agonists (NOT RECOMMENDED)

Issue: Dual GLP-1/GIP/glucagon